JAMA Neurology published Phase 2b PARADIGM results for PrimeC in ALS, showing slower functional decline, fewer ALS-related complications and longer survival. NeuroSense is preparing a Phase 3 trial and received Brazilian patent protection through October 2042.
PrimeC, an oral combination therapy, showed safety and signals of clinical benefit in a phase 2b trial, while PLL001, a gut-targeting therapy, demonstrated positive safety and tolerability in a phase I/II study for amyotrophic lateral sclerosis.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597902 |
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction |
NOT_YET_RECRUITING | PHASE2 |
| NCT07559682 |
Efficacy of Selective COX-2 Inhibitors in Relieving Orthodontic Pain |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06997068 |
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population |
RECRUITING | PHASE2 |
| NCT06699966 |
Stony Brook Medicine Anti-Inflammatory Trial |
NOT_YET_RECRUITING | PHASE4 |
| NCT06245109 |
Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis |
RECRUITING | PHASE4 |
| NCT02993029 |
99Tc-MDP Treatment for Knee Osteoarthritis |
RECRUITING | NA |
| NCT01150045 |
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery |
COMPLETED | PHASE3 |
